ALEC [NASD]
Alector, Inc.
Index- P/E- EPS (ttm)-0.34 Insider Own4.20% Shs Outstand82.10M Perf Week10.73%
Market Cap816.08M Forward P/E- EPS next Y-1.59 Insider Trans-0.01% Shs Float73.16M Perf Month13.72%
Income-28.00M PEG- EPS next Q-0.47 Inst Own83.00% Short Float8.03% Perf Quarter-30.23%
Sales227.40M P/S3.59 EPS this Y81.50% Inst Trans0.42% Short Ratio8.37 Perf Half Y-55.31%
Book/sh3.26 P/B3.10 EPS next Y-30.00% ROA-3.80% Target Price27.62 Perf Year-51.72%
Cash/sh10.76 P/C0.94 EPS next 5Y- ROE-10.60% 52W Range7.50 - 43.32 Perf YTD-51.04%
Dividend- P/FCF1.69 EPS past 5Y-15.40% ROI-12.40% 52W High-76.66% Beta1.08
Dividend %- Quick Ratio6.20 Sales past 5Y246.30% Gross Margin- 52W Low34.80% ATR0.64
Employees237 Current Ratio6.20 Sales Q/Q497.60% Oper. Margin-12.70% RSI (14)56.98 Volatility8.21% 6.89%
OptionableYes Debt/Eq0.00 EPS Q/Q18.70% Profit Margin-12.70% Rel Volume0.87 Prev Close10.74
ShortableYes LT Debt/Eq0.00 EarningsMay 05 AMC Payout- Avg Volume702.08K Price10.11
Recom1.90 SMA2011.50% SMA508.01% SMA200-40.12% Volume611,524 Change-5.87%
Apr-13-22Initiated Goldman Sell $9
Mar-08-22Downgrade Stifel Buy → Hold $32 → $18
Sep-27-21Initiated William Blair Outperform
Jan-15-21Resumed BofA Securities Buy $35
Jun-24-20Initiated H.C. Wainwright Buy $41
Apr-28-20Initiated Goldman Buy $32
Mar-06-20Initiated Citigroup Buy $40
Feb-27-20Initiated Barclays Overweight $36
Feb-19-20Initiated Stifel Buy $44
Nov-21-19Initiated BTIG Research Buy $28
Mar-04-19Initiated SVB Leerink Outperform
Mar-04-19Initiated Morgan Stanley Overweight $27
Mar-04-19Initiated BofA/Merrill Buy $26
Mar-04-19Initiated Barclays Overweight $27
Jun-08-22 07:00AM  
May-28-22 08:20AM  
May-27-22 04:30PM  
May-05-22 06:25PM  
04:05PM  
May-04-22 07:00AM  
May-02-22 07:47AM  
Apr-27-22 03:03PM  
Mar-29-22 04:05PM  
Mar-15-22 12:04PM  
08:00AM  
Mar-09-22 07:00AM  
Mar-08-22 07:00AM  
Mar-01-22 04:30PM  
04:05PM  
Feb-24-22 06:50PM  
04:05PM  
Feb-17-22 03:02PM  
Feb-14-22 04:30AM  
Feb-07-22 08:30AM  
Feb-01-22 11:13AM  
Jan-11-22 01:30AM  
01:30AM  
Jan-10-22 11:07AM  
Jan-03-22 04:30PM  
Jan-02-22 06:32AM  
Dec-24-21 12:38AM  
Dec-16-21 11:03AM  
Dec-15-21 08:30AM  
Dec-11-21 09:15AM  
Dec-10-21 04:30AM  
Nov-15-21 11:34AM  
Nov-12-21 01:50PM  
07:00AM  
Nov-11-21 11:23AM  
09:06AM  
Nov-10-21 08:30AM  
Nov-08-21 04:05PM  
Nov-04-21 08:56PM  
04:05PM  
Nov-03-21 04:50PM  
Nov-02-21 03:01PM  
Oct-27-21 05:06AM  
Oct-04-21 06:47AM  
Sep-28-21 08:30AM  
Sep-09-21 08:30AM  
Sep-08-21 03:20PM  
02:32PM  
12:17PM  
12:02PM  
10:16AM  
Sep-07-21 04:30PM  
Sep-02-21 07:00AM  
Aug-05-21 01:13AM  
Aug-03-21 06:35PM  
05:09PM  
03:00PM  
Jul-29-21 10:10AM  
Jul-21-21 04:35PM  
Jul-18-21 03:11AM  
Jul-12-21 07:24AM  
Jul-09-21 08:10AM  
01:35AM  
Jul-07-21 12:56PM  
04:58AM  
Jul-06-21 05:49PM  
Jul-05-21 10:14AM  
08:20AM  
Jul-02-21 02:54PM  
01:38PM  
12:22PM  
11:09AM  
10:41AM  
08:26AM  
08:04AM  
07:38AM  
07:34AM  
07:30AM  
Jul-01-21 08:00PM  
Jun-03-21 04:05PM  
Jun-02-21 06:31AM  
May-26-21 04:05PM  
May-10-21 01:05AM  
May-06-21 04:05PM  
May-05-21 08:05PM  
04:05PM  
03:00PM  
01:32AM  
Mar-30-21 01:23PM  
Mar-25-21 04:05PM  
Mar-23-21 01:53PM  
Mar-04-21 04:05PM  
Feb-28-21 01:36AM  
Feb-25-21 04:05PM  
Jan-25-21 08:30AM  
Jan-20-21 04:15PM  
Jan-07-21 04:05PM  
Dec-29-20 11:42PM  
Dec-11-20 08:56AM  
Nov-12-20 11:18AM  
Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease; and AL003, which is in Phase I clinical trial for the treatment of Alzheimer's disease. In addition, its products in development stage include AL044 that targets MS4A4A, a risk gene for Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
King RobertChief Development OfficerJun 02Sale8.711771,542529,471Jun 06 04:52 PM
King RobertChief Development OfficerMar 01Sale15.572874,468528,404Mar 03 05:41 PM
SULIMAN SHEHNAAZPresident and COODec 13Option Exercise17.2375,0001,292,250177,598Dec 14 08:23 PM
SULIMAN SHEHNAAZPresident and COODec 13Sale21.2475,0001,593,149102,598Dec 14 08:23 PM
SULIMAN SHEHNAAZPresident and COODec 10Option Exercise17.2375,0001,292,250177,598Dec 14 08:23 PM
SULIMAN SHEHNAAZPresident and COODec 10Sale21.7675,0001,632,167102,598Dec 14 08:23 PM
SULIMAN SHEHNAAZPresident and COODec 09Option Exercise17.2375,0001,292,250177,598Dec 10 07:20 PM
SULIMAN SHEHNAAZPresident and COODec 09Sale22.8275,0001,711,843102,598Dec 10 07:20 PM
SULIMAN SHEHNAAZPresident and COODec 08Option Exercise12.0975,000906,493177,598Dec 10 07:20 PM
SULIMAN SHEHNAAZPresident and COODec 08Sale22.7975,0001,709,316102,598Dec 10 07:20 PM
King RobertChief Development OfficerDec 01Sale20.092505,022528,691Dec 03 05:08 PM
Rosenthal ArnonChief Executive OfficerNov 11Sale25.0055,0001,375,0001,972,875Nov 12 06:36 PM
Rosenthal ArnonChief Executive OfficerNov 10Sale25.0055,0001,375,0002,027,875Nov 12 06:36 PM
Rosenthal ArnonChief Executive OfficerNov 09Sale25.00100,0002,500,000652,500Nov 10 07:07 PM
Rosenthal ArnonChief Executive OfficerNov 08Sale25.00100,0002,500,000667,500Nov 10 07:07 PM
Rosenthal ArnonChief Executive OfficerNov 05Sale25.00100,0002,500,000682,500Nov 08 06:39 PM
Rosenthal ArnonChief Executive OfficerNov 04Sale25.00100,0002,500,000697,500Nov 08 06:39 PM
Rosenthal ArnonChief Executive OfficerSep 23Sale25.109,625241,5672,302,875Sep 23 09:12 PM
Rosenthal ArnonChief Executive OfficerSep 22Sale25.33100,0002,533,1882,312,500Sep 23 09:12 PM
Rosenthal ArnonChief Executive OfficerSep 21Sale26.11100,0002,611,4372,412,500Sep 22 04:54 PM
Rosenthal ArnonChief Executive OfficerSep 20Sale25.80100,0002,580,3912,512,500Sep 22 04:54 PM
Paul RobertChief Medical OfficerAug 09Option Exercise10.6922,950245,245257,269Aug 11 06:23 PM
Paul RobertChief Medical OfficerAug 09Sale27.1822,950623,767234,319Aug 11 06:23 PM
SCHELLER RICHARD HDirectorAug 05Option Exercise10.1456,260570,47656,260Aug 09 06:13 PM
SCHELLER RICHARD HDirectorAug 05Sale27.6856,2601,557,3410Aug 09 06:13 PM
Paul RobertChief Medical OfficerJul 07Option Exercise12.1529,749361,340264,068Jul 08 06:24 PM
Paul RobertChief Medical OfficerJul 07Sale38.7029,7491,151,238234,319Jul 08 06:24 PM
Paul RobertChief Medical OfficerJul 06Option Exercise17.1530,000514,500264,319Jul 08 06:24 PM
Yu CalvinVice President, FinanceJul 06Option Exercise13.033,33443,42980,020Jul 07 07:38 PM
Yu CalvinVice President, FinanceJul 06Sale34.653,334115,52376,686Jul 07 07:38 PM
Paul RobertChief Medical OfficerJul 06Sale37.3130,0001,119,167234,319Jul 08 06:24 PM
Paul RobertChief Medical OfficerJul 02Option Exercise17.1517,326297,141264,319Jul 06 06:14 PM
King RobertChief Development OfficerJul 02Option Exercise9.1560,000549,000582,317Jul 07 07:02 PM
Yu CalvinVice President, FinanceJul 02Option Exercise13.1360,840798,948187,526Jul 07 07:38 PM
Yu CalvinVice President, FinanceJul 02Sale32.74110,8403,629,07876,686Jul 07 07:38 PM
King RobertChief Development OfficerJul 02Sale31.1460,0001,868,400522,317Jul 07 07:02 PM
SCHELLER RICHARD HDirectorJul 02Sale31.149,981310,8080Aug 09 06:13 PM
Paul RobertChief Medical OfficerJul 02Sale31.1430,000934,200234,319Jul 06 06:14 PM
Paul RobertChief Medical OfficerJul 01Sale22.2326,726594,124246,993Jul 06 06:14 PM